Daniel King, MD, PhD, discusses the implications of the RASolute 302 study of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma.
Daniel King, MD, PhD
Advertisement
Articles by Daniel King, MD, PhD
Daniel King, MD, PhD, discusses the need to develop less-toxic regimens for advanced gastrointestinal cancers.
Daniel King, MD, PhD, discusses socioeconomic disparities causing delays in germline genetic testing for patients with pancreatic cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
4
The OncFive: Top Oncology Articles for the Week of 7/12
5